#USA #Seattle #DARPA #RxMP Therapeutics #RMP-402

Groundbreaking Funding for Hemorrhage Control Therapy

In a significant development in the field of medical therapeutics, RxMP Therapeutics, Inc. has been awarded a contract of up to $10.7 million by the U.S. Department of War through the Defense Advanced Research Projects Agency (DARPA). This funding is aimed at advancing the company’s flagship product, RMP-402, which is engineered to rapidly control hemorrhage and excessive bleeding.

The Innovative Solution: RMP-402

RMP-402 is a pioneering hemostatic biomimetic therapy, crafted using manufactured allogeneic red cell membrane particles. This innovative approach mimics particles that naturally exist within human blood, allowing RMP-402 to be administered intravenously. The target of this therapy is to accelerate hemostasis at sites of active bleeding while minimizing the risks associated with off-target clotting.

This novel solution is intended for dual-use scenarios in both military and civilian contexts, particularly in situations where traditional blood products are scarce or face logistic hurdles such as storage and availability.

Objectives of the DARPA Grant

The funds from DARPA will facilitate the attainment of critical preclinical and regulatory milestones necessary for the transition of RMP-402 into first-in-human clinical trials. Specific areas of focus include:

• - Completing essential IND-enabling development activities.
• - Scaling up manufacturing to meet anticipated demands for both military operations and public health crises.
• - Preparing the Investigational New Drug (IND) application package.

This program aligns with DARPA’s Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) initiative, which seeks to propel the development of technologies that can produce shelf-stable blood analogs. This means the products can be manufactured at scale and authorized for regulatory use, thus bolstering capabilities to manage hemorrhage in critical situations where conventional solutions are not available.

Impact of the Funding

Dr. Rifat Pamukcu, President and CEO of RxMP Therapeutics, emphasized the importance of this contract in advancing both the company’s goals and public health. The grant marks a turning point, providing RxMP with the necessary resources to finalize IND-enabling research, while showcasing the potential for RMP-402 to be produced at a volume sufficient for widespread use.

Furthermore, the contract opens doors for the possibility of an Emergency Use Authorization (EUA) for use in combat casualty care, indicating the product's potential to revolutionize how excessive bleeding is managed, especially where conventional blood products cannot be easily deployed.

RxMP Therapeutics: A Vision for the Future

Founded to develop effective solutions for hemorrhage control, RxMP Therapeutics focuses on addressing the urgent need in global trauma and surgical markets, which could potentially exceed $12 billion annually. The firm is positioned to provide innovative strategies that can save lives by addressing uncontrolled bleeding, a leading cause of morbidity and preventable death worldwide.

As RxMP Therapeutics embarks on this significant journey with the support from DARPA, the medical community awaits the results, hoping for advancements that could drastically reduce morbidity in emergency healthcare settings, both military and civilian.

For further information, visit RxMP Therapeutics.